FDA grants Dupixent Priority Review for sinusitis
US regulators have accepted Sanofi’s Dupixent for Priority Review as a treatment for rhinosinusitis with nasal polyps.
Read More
Tag: severe chronic rhinosinusitis
- GSK wins US approval for ROS1 lung cancer therapy
- Lundbeck secures FDA Fast Track for narcolepsy drug
- R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
- Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
- Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
